Skip to main content

8 Result(s)

within Masahiro Sekimizu Remove this filter

and

  1. No Access

    Article

    Phase 2 study of combination chemotherapy with bortezomib in children with relapsed and refractory acute lymphoblastic leukemia

    Treatment outcomes for children with relapsed and refractory acute lymphoblastic leukemia (R/R-ALL) remain poor, and the optimal induction therapy has not been determined. Bortezomib is a proteasome inhibitor ...

    Naoyuki Miyagawa, Hiroaki Goto, Atsushi Ogawa… in International Journal of Hematology (2023)

  2. Article

    Correction to: A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1)

    Hideki Nakayama, Chitose Ogawa, Masahiro Sekimizu… in International Journal of Hematology (2023)

    Download PDF (376 KB) View Article

  3. No Access

    Article

    A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1)

    Inotuzumab ozogamicin (InO) is a CD22-directed antibody conjugated with calicheamicin approved for adult relapsed or refractory CD22-positive acute lymphoblastic leukemia (ALL). This phase 1 study primarily ai...

    Hideki Nakayama, Chitose Ogawa, Masahiro Sekimizu… in International Journal of Hematology (2022)

  4. Article

    Open Access

    Tranilast for advanced heart failure in patients with muscular dystrophy: a single-arm, open-label, multicenter study

    The transient receptor potential cation channel subfamily V member 2 (TRPV2) is a stretch-sensitive calcium channel. TRPV2 overexpression in the sarcolemma of skeletal and cardiac myocytes causes calcium influ...

    Tsuyoshi Matsumura, Hiroya Hashimoto… in Orphanet Journal of Rare Diseases (2022)

    Download PDF (1276 KB) View Article

  5. No Access

    Article

    Phase I study of brentuximab vedotin (SGN-35) in Japanese children with relapsed or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large cell lymphoma

    Data on the treatment of pediatric patients with brentuximab vedotin are limited. The aims of the present study were to assess the safety and tolerability of brentuximab vedotin in Japanese children with relap...

    Yuhki Koga, Masahiro Sekimizu, Akihiro Iguchi… in International Journal of Hematology (2020)

  6. Article

    Open Access

    Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol

    Hodgkin’s lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) are the two most common tumors expressing CD30. Internationally, a clinical study that is being conducted involving adults with recurrent or re...

    Masahiro Sekimizu, Akihiro Iguchi, Tetsuya Mori, Yuhki Koga, Akiko Kada… in BMC Cancer (2018)

    Download PDF (402 KB) View Article

  7. No Access

    Article

    Pediatric follicular lymphoma in Japan

    Follicular lymphoma (FL) is quite rare in children. There have been only two major reports on pediatric FL. The present retrospective study on pediatric FL in Japan, including FL with diffuse large B cell lymp...

    Ryoji Kobayashi, Fumiko Tanaka, Atsuko Nakazawa… in International Journal of Hematology (2017)

  8. No Access

    Article

    Hematopoietic stem cell transplantation for pediatric mature B-cell acute lymphoblastic leukemia with non-L3 morphology and MLL-AF9 gene fusion: three case reports and review of the literature

    Mature B-cell acute lymphoblastic leukemia (B-ALL) is typically associated with French-American-British (FAB)-L3 morphology and MYC gene rearrangement. However, rare cases of mature B-ALL with non-L3 morphology a...

    Takeo Sarashina, Haruko Iwabuchi, Naoyuki Miyagawa… in International Journal of Hematology (2016)